← Back to Search

Nonsteroidal Anti-inflammatory Drug

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

Phase 1 & 2
Waitlist Available
Led By John Bauer, PhD
Research Sponsored by Hong Huang
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months of corrected gestational age

Summary

Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) are brain lesions that commonly occur in preterm infants and are well-recognized major contributors to long-term brain injury and related disabilities later in life. Despite its prevalence, long term consequences, and enormous medical and social costs, mechanisms of IVH and optimal strategies to prevent or treat its occurrence are poorly defined, especially for extremely premature infants. Only one medical therapy, prophylactic indomethacin during the first 3 days of life, has been shown to prevent or decrease the severity of IVH in preterm infants, but its use is limited by toxic side effects and debatable effects on long-term outcomes. Several small studies and case reports suggest that delayed umbilical cord-clamping (DCC) may also decrease the incidence of IVH in premature infants, but thus far these trials have indomethacin treatment mixed within their cord clamping protocols. The investigators are conducting a randomized, blinded investigation of 4 treatment groups: 1) Control (no intervention); 2) DCC alone; 3) Prophylactic indomethacin alone; 4) Combination of DCC/indomethacin, with respect to survival, IVH or PVL incidence and severity, neurodevelopmental outcomes, and relevant mechanistic effects. With the steady rise in extreme prematurity births and clear links of IVH to long-term disabilities there is a need to improve care for these patients. This multi- disciplinary project addresses an important medical problem for an understudied patient population, where the current practice has clear limitations.

Eligible Conditions
  • Brain Damage
  • Intraventricular Hemorrhage
  • Traumatic Brain Injury
  • Kidney Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months of corrected gestational age
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months of corrected gestational age for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL
Secondary study objectives
Number of Participants With Acute Kidney Injury
Other study objectives
Circulating Progenitor Cell Subpopulations
Hematological Status
Inflammatory Stress
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: indomethacin iv & delayed cord clampExperimental Treatment2 Interventions
A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
Group II: delay cord clamp & placebo IV solutionExperimental Treatment2 Interventions
A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
Group III: immediate cord clamp & indomethacin IVActive Control2 Interventions
Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
Group IV: immediate cord clamp & placebo IV solutionPlacebo Group2 Interventions
This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indomethacin
2011
Completed Phase 4
~5790
delay in umbilical cord clamp at birth
2014
Completed Phase 2
~260
placebo infusion
2014
Completed Phase 3
~720

Find a Location

Who is running the clinical trial?

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,062 Previous Clinical Trials
2,746,011 Total Patients Enrolled
Hong HuangLead Sponsor
Vicki Whitehead, RNStudy DirectorUK Section of Neonatology
John Bauer, PhDPrincipal InvestigatorUK Department of Pediatrics
Hong Huang, MD-PhDStudy DirectorUniversity of Kentucky Section of Neonatology
~23 spots leftby Dec 2025